MacroGenics, Inc. (MGNX) Provides Update On Corporate Progress And 2013 Financial Results
3/21/2014 8:54:03 AM
ROCKVILLE, Md., March 20, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today provided a corporate progress update and reported financial results for the year ended December 31, 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by